Hemoxymed, Molecular Geriatrics deal

HMYD completed its previously announced merger with Molecular Geriatrics (see BioCentury, Aug. 5). HMYD issued 22.8 million shares, thus valuing Molecular Geriatrics at $4.56 million based on HMYD’s F...